Accéder au contenu
Merck
Toutes les photos(3)

Documents

C1801

Sigma-Aldrich

Monoclonal Anti-Cytokeratin, pan antibody produced in mouse

clone PCK-26, ascites fluid

Synonyme(s) :

Monoclonal Anti-pan-Cytokeratin

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

Conjugué

unconjugated

Forme d'anticorps

ascites fluid

Type de produit anticorps

primary antibodies

Clone

PCK-26, monoclonal

Contient

15 mM sodium azide

Espèces réactives

human, chicken, snake, hamster, pig, goat, feline, bovine, carp, rat, rabbit, canine, lizard, sheep, mouse, guinea pig

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:300
immunohistochemistry (frozen sections): suitable
indirect immunofluorescence: 1:300 using protease-idgested, formalin-fixed, paraffin-embedded sections of human or animal tissues
western blot: suitable

Isotype

IgG1

Conditions d'expédition

dry ice

Température de stockage

−20°C

Modification post-traductionnelle de la cible

unmodified

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Cytokeratin belongs to the member of intermediate filament (IF) protein family.
Cytokeratins, a group comprising at least 29 different proteins are characteristic of epithelial and trichocytic cells. Cytokeratin 1, 5, 6, and 8 are members of the type II neutral-to-basic subfamily. Cytokeratin peptide 1 (68 kDa) is expressed together with cytokeratin 10 in the suprabasal cell layers or the differentiation compartment of the epidermis. Its expression increases with epidermal maturation and it is modified post-translationally in the terminally differentiated keratinocytes of the stratum corneum. Cytokeratin peptide 5 (58 kDa) is the primary type II keratin in stratified epithelia while cytokeratin type 8 (52 kDa) is a major type II keratin in simple epithelia. Cytokeratin 6 (56 kDa) is a "hyperproliferation" cytokeratin expressed in tissues with natural or pathological high turnover.

Spécificité

The antibody recognizes an epitope located on the Type II cytokeratins 1, 5, 6, and 8. PCK-26 is a broad spectrum antibody which reacts specifically with a variety of normal, reactive, and neoplastic epithelial tissues. The antibody reacts with simple, cornifying, and non-cornifying squamous epithelia and pseudostratified epithelia.

Immunogène

cytokeratin from human epidermis.

Application

Monoclonal antibodies to cytokeratins are specific markers of epithelial cell differentiation and have been widely used as tools in tumor identification and classification. Monoclonal Anti-Cytokeratin, pan is a broadly reactive group-type antibody which recognizes an epitope present in most human epithelial tissues. It facilitates the typing of normal, metaplastic and neoplastic cells and it may aid in the discrimination of carcinomas and non-epithelial tumors such as sarcomas, lymphomas and neural tumors. It is also useful in detecting micro-metastases in lymph nodes and other tissues and for determining the origin of poorly differentiated tumors.
Monoclonal Anti-Cytokeratin, pan may be used for the localization of cytokeratins using various immunochemical assays such as immunoblotting, dot blotting, and immunohistochemstry (immunofluorescence and immunoenzymatic staining).
A minimum antibody titer of 1:300 was determined by indirect immunofluorescent staining of protease digested, formalin-fixed, paraffin-embedded sections of human or animal tissues.

Actions biochimiques/physiologiques

Pan-cytokeratin along with the expression of CXCR4, may be a prognostic biomarker for non-small cell lung cancer (NSCLC).

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Marcus Ruscetti et al.
Cancer research, 75(13), 2749-2759 (2015-05-08)
The epithelial-mesenchymal transition (EMT) has been postulated as a mechanism by which cancer cells acquire the invasive and stem-like traits necessary for distant metastasis. However, direct in vivo evidence for the role of EMT in the formation of cancer stem-like
Anup Sood et al.
Viruses, 12(8) (2020-07-29)
Over the last 15 years, advances in immunofluorescence-imaging based cycling methods, antibody conjugation methods, and automated image processing have facilitated the development of a high-resolution, multiplexed tissue immunofluorescence (MxIF) method with single cell-level quantitation termed Cell DIVETM. Originally developed for
Clinical utility of cytokeratins as tumor markers
Barak V, et al.
Clinical Biochemistry, 37(7), 529-540 (2004)
Christopher W Helsen et al.
Nature communications, 9(1), 3049-3049 (2018-08-05)
Engineering T cells with chimeric antigen receptors (CARs) is an effective method for directing T cells to attack tumors, but may cause adverse side effects such as the potentially lethal cytokine release syndrome. Here the authors show that the T
CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer
Reckamp KL, et al.
BMC Cancer, 9(1), 213-213 (2009)

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique